IGF-1 LR3 0.1 mg

IGF-1 LR3 0.1 mg — an engineered growth factor analogue built to evade its binding Proteins
Long R3 IGF-1 is not simply insulin-like growth factor 1 in a vial. It is a deliberately re-engineered analogue designed to slip past the binding proteins that normally control the native molecule.

What is IGF-1 LR3?

IGF-1 LR3 is a recombinant analogue of insulin-like growth factor 1 carrying two structural modifications: a thirteen amino acid N-terminal extension and a substitution of arginine for glutamic acid at position three. Together these changes sharply reduce its affinity for the IGF binding proteins that sequester native IGF-1 in circulation. The research consequence is a molecule with markedly greater free availability and a longer functional window — which is precisely why it is favoured in cell culture and preclinical systems where binding-protein interference would otherwise obscure the signal being measured.

Research interest

• Cell proliferation and growth — widely used as a supplement in research cell-culture systems studying IGF-1 receptor signalling.
• Binding-protein biology — a key tool for researchers isolating receptor-mediated effects from binding-protein-mediated regulation.
• Tissue repair models — investigated in preclinical contexts examining anabolic and regenerative signalling.
• Metabolic crosstalk — of interest to groups studying the overlap between IGF-1 and insulin receptor pathways.
• Protein-engineering reference — frequently cited as an example of rational modification to alter a protein's pharmacokinetic behaviour.

At 0.1 mg per vial this is a potent, low-mass growth factor, and small absolute quantities make handling accuracy and material purity disproportionately important. Recombinant proteins of this class are also structurally delicate — correct folding, not just correct sequence, determines receptor activity.

Specifications

• Content: 0.1 mg of active substance per vial
• Form: Lyophilised recombinant protein (vial)
• Purity: Pharmaceutical-grade, batch-tested and lot-traceable
• Presentation: Sealed, tamper-evident single vial
• Storage: -20 °C sealed; 2-8 °C short-term

Handling & storage

Store sealed lyophilised vials at -20 °C for long-term stability; short periods at 2-8 °C are generally tolerated during transit and handling. Keep vials sealed, protected from light and away from moisture and repeated temperature swings. Handle as a delicate recombinant protein. Keep sealed and frozen for long-term storage, equilibrate to room temperature before opening, and reconstitute gently under the laboratory's own validated protocol with an appropriate sterile diluent. Aliquot to avoid repeated freeze-thaw, which is particularly damaging to folded growth factors.

The Rogue standard

• Analytically verified — every lot tested for purity and identity, with traceable batch records.
• Sealed and authentic — European supply chain, no grey-market intermediaries, no relabelled stock.
• Built for repeatable work — stable lot quality so results are not confounded by material variance.
• Discreet, tracked delivery — fast dispatch across the EU in unbranded packaging.

For research purposes only. Not a medicinal product. Not for human or veterinary consumption. Intended for qualified laboratory research use only. No statement on this page is a medical claim, and no administration, dosing or protocol guidance is offered or implied.

Related: Peptides · Tirzepatide · Cagrilintide + Semaglutide 5 mg + 5 mg